NS5B
From Proteopedia
(Difference between revisions)
Line 15: | Line 15: | ||
[http://www.nature.com/nrmicro/journal/v5/n6/fig_tab/nrmicro1645_F4.html This image] is a depiction of each of the protein products of NS5B genomic translation. The proteins coded for by the hepatitis C virus (HCV) genome all associate with the ER membrane. The proteins are translated as one large poly-protein that is enzymatically cleaved by both host and viral proteases. Of the several proteins that are coded for by HCV, three functions have been identified as relevant drug targets, these are the NS3 protease and helicase domains and the NS5B RNA dependent RNA polymerase. Currently the therapy for HCV is interferon therapy often in combination with ribavirin. This therapy however is inadequate; it is not effective in each genotype of HCV, it is not well tolerated, and is expensive. For these reasons many academic and industrial laboratories have been working on developing novel inhibitors of NS5B. | [http://www.nature.com/nrmicro/journal/v5/n6/fig_tab/nrmicro1645_F4.html This image] is a depiction of each of the protein products of NS5B genomic translation. The proteins coded for by the hepatitis C virus (HCV) genome all associate with the ER membrane. The proteins are translated as one large poly-protein that is enzymatically cleaved by both host and viral proteases. Of the several proteins that are coded for by HCV, three functions have been identified as relevant drug targets, these are the NS3 protease and helicase domains and the NS5B RNA dependent RNA polymerase. Currently the therapy for HCV is interferon therapy often in combination with ribavirin. This therapy however is inadequate; it is not effective in each genotype of HCV, it is not well tolerated, and is expensive. For these reasons many academic and industrial laboratories have been working on developing novel inhibitors of NS5B. | ||
- | <scene name='NS5B/Cv/ | + | <scene name='NS5B/Cv/5'>Much of the x-ray crystallography work that has gone into NS5B to date</scene> (Ligands are from: 1C2P, 1CSJ, 1GX5, 1GX6, 1NB4, 1NB6, 1NB7, 1HNU, 1NHV, 1OS5, 1QUV, 1YUY, 1YV2, 1YVF, 1YVX, 1YVZ, 1Z4U, 2AWZ, 2AX0, 2AX1, 2BRK, 2BRL, 2D3U, 2D3Z, 2D41, 2GIQ, 2GIR, 2HWH, 2HWI, 2I1R, 2IJN, 2JC0, 2JC1, 3BR9, 3BSA, 3BSC, 3CIZ, 3CJ0, 3CJ2, 3CJ3, 3CJ4, 3CJ5). Superpositions in the scene by Rould MA, and Villanueva NL. Each of the forty three structures included in the superposition contain at least one ligand, the ligands range from ions and small molecules to nucleotides and non-nucleoside analogue inhibitors. Positioning the structure in the familiar orientation with the <scene name='NS5B/Ns5b_with_ligands/6'>domains</scene> colored as above, it is obvious that there are two primary areas where ligands are clustering. Several nucleotides, oligonucleotides and non-nucleoside analogue inhibitors can be found near the <scene name='NS5B/Ns5b_with_ligands/4'>active site</scene>. There is another site that is about 30-35Å from the active site, an <scene name='NS5B/Ns5b_with_ligands/5'>allosteric site</scene>, where again ligands are clustering. There is a rGTP binding site here that seems to activate the enzyme and a nearby site where inhibitors bind and disrupt the activity of the enzyme. |
The inhibitors that bind near the <scene name='NS5B/Ns5b_with_ligands/4'>active site</scene> are thought to work by disrupting the ''primer grip'' site causing an inability of the enzyme to efficiently hold and extend a growing primer strand. The inhibitors that bind near the <scene name='NS5B/Ns5b_with_ligands/5'>allosteric site</scene> work through a poorly understood mechanism, several explanations for their ability to inhibit the enzyme have been proposed. The commonly proposed explanations are that these inhibitors lock the enzyme in an inactive conformation, inhibit binding of the rGTP that binds in the area and has been shown to stimulate activity, or that this interface is critical in protein-protein interactions and disruption of these interactions by the inhibitors disrupts an oligomerization of several NS5B protomers thus making each less efficient. | The inhibitors that bind near the <scene name='NS5B/Ns5b_with_ligands/4'>active site</scene> are thought to work by disrupting the ''primer grip'' site causing an inability of the enzyme to efficiently hold and extend a growing primer strand. The inhibitors that bind near the <scene name='NS5B/Ns5b_with_ligands/5'>allosteric site</scene> work through a poorly understood mechanism, several explanations for their ability to inhibit the enzyme have been proposed. The commonly proposed explanations are that these inhibitors lock the enzyme in an inactive conformation, inhibit binding of the rGTP that binds in the area and has been shown to stimulate activity, or that this interface is critical in protein-protein interactions and disruption of these interactions by the inhibitors disrupts an oligomerization of several NS5B protomers thus making each less efficient. |
Revision as of 10:05, 9 April 2013
|
References
- Li H, Tatlock J, Linton A, Gonzalez J, Borchardt A, Dragovich P, Jewell T, Prins T, Zhou R, Blazel J, Parge H, Love R, Hickey M, Doan C, Shi S, Duggal R, Lewis C, Fuhrman S. Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4834-8. Epub 2006 Jul 7. PMID:16824756 doi:10.1016/j.bmcl.2006.06.065
- Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3392-6. PMID:1849654
- Doublie S, Tabor S, Long AM, Richardson CC, Ellenberger T. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 A resolution. Nature. 1998 Jan 15;391(6664):251-8. PMID:9440688 doi:http://dx.doi.org/10.1038/34593
- O'Farrell D, Trowbridge R, Rowlands D, Jager J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol. 2003 Feb 28;326(4):1025-35. PMID:12589751
- Doublie S, Tabor S, Long AM, Richardson CC, Ellenberger T. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 A resolution. Nature. 1998 Jan 15;391(6664):251-8. PMID:9440688 doi:http://dx.doi.org/10.1038/34593
- Kim YC, Russell WK, Ranjith-Kumar CT, Thomson M, Russell DH, Kao CC. Functional analysis of RNA binding by the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem. 2005 Nov 11;280(45):38011-9. Epub 2005 Sep 14. PMID:16166071 doi:10.1074/jbc.M508145200
- Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007 Jun;5(6):453-63. Epub 2007 May 8. PMID:17487147 doi:10.1038/nrmicro1645
- Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, Morin N, Nguyen-Ba N, Alaoui-Ismaili MH, Bethell RC, James MN. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem. 2003 Mar 14;278(11):9489-95. Epub 2002 Dec 30. PMID:12509436 doi:10.1074/jbc.M209397200
- Pfefferkorn JA, Greene ML, Nugent RA, Gross RJ, Mitchell MA, Finzel BC, Harris MS, Wells PA, Shelly JA, Anstadt RA, Kilkuskie RE, Kopta LA, Schwende FJ. Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. Bioorg Med Chem Lett. 2005 May 16;15(10):2481-6. PMID:15863301 doi:10.1016/j.bmcl.2005.03.066
Proteopedia Page Contributors and Editors (what is this?)
Nicolas Villanueva, Alexander Berchansky, Kody Witham, Michal Harel, David Canner